Global Hypophosphatasia Treatment Market
Global hypophosphatasia treatment market is expected to reach USD 1,812.12 million by 2031, from USD 1,329.26 million in 2023 growing at the CAGR of 4.4% in the forecast period of 2024 to 2031.
Market SegmentationGlobal Hypophosphatasia Treatment Market, By Types (Odontohypophosphatasia, Pseudohypophosphatasia, and Others), Therapy Type (Enzyme Replacement Therapy and Supportive Therapy), Route of Administration (Injectable and Oral), End User (Hospitals, Speciality Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (UU.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Turkey, Belgium, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, and rest of Middle East and Africa) – Industry Trends and Forecast to 2031
Overview of Global Hypophosphatasia Treatment Market DynamicsDrivers
• Increasing incidence rate for hypophosphatasia
• Continuous increase in clinical trials and pipeline products
• Favorable reimbursement policies
Restraints
• High cost of treatment
• Complex treatment regimen
Opportunities
• Increasing adoption of various types of advanced therapy
• Initiatives by the government to create awareness
Challenges
• Impact of discontinuation of drug treatment and related adverse effect
• Genetic variability and disease complexity
Market PlayersThe key market players for global hypophosphatasia treatment market are listed below:• AstraZeneca
• Pfizer Inc.
• Abbott
• Novartis AG
• AM-Pharma B.V.
• Be Biopharma
• PuREC
• Rallybio
• Rampart Bioscience, Inc.
• Roivant Sciences Ltd.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.